Recent studies revealed that SGLT2 inhibitors have therapeutic effects on NASH in rodent models,12, 13, 14 raising the possibility that they may be beneficial in treating NASH associated with T2DM. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatohepatitis.